@article{0011c69fa20840939f5c0a51e4b54dca,
title = "A potently neutralizing antibody protects mice against SARS-CoV-2 infection",
abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.",
author = "Alsoussi, {Wafaa B.} and Turner, {Jackson S.} and Case, {James B.} and Haiyan Zhao and Schmitz, {Aaron J.} and Zhou, {Julian Q.} and Chen, {Rita E.} and Tingting Lei and Rizk, {Amena A.} and McIntire, {Katherine M.} and Winkler, {Emma S.} and Fox, {Julie M.} and Kafai, {Natasha M.} and Thackray, {Larissa B.} and Hassan, {Ahmed O.} and Fatima Amanat and Florian Krammer and Watson, {Corey T.} and Kleinstein, {Steven H.} and Fremont, {Daved H.} and Diamond, {Michael S.} and Ellebedy, {Ali H.}",
note = "Funding Information: of Genetics at Washington University School of Medicine]), the National Center for Research Resources (an Institute for Clinical and Translational Science/Clinical and Translational Sciences Award, Grant UL1 TR000448, to the Genome Technology Access Center in the Department of Genetics at Washington University School of Medicine), and a Helen Hay Whitney postdoctoral fellowship (to J.B.C.). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NIAID or NIH. Funding Information: This work was supported or partially supported by the National Institute of Allergy and Infectious Diseases (NIAID) (R21 AI139813 and U01 AI141990, to the Ellebedy laboratory; HHSN272201700060C, to the Fremont laboratory; 75N93019C00062, to the Fremont and Diamond laboratories; 5T32CA009547, to J.S.T.; and R01AI104739, to the Kleinstein laboratory), the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) (Contract HHSN272201400008C, to the Ellebedy and Krammer laboratories), the National Institutes of Health (NIH) (Grant R01 AI127828, to the Diamond laboratory), the Defense Advanced Research Projects Agency (HR001117S0019, to the Diamond laboratory), the Collaborative Influenza Vaccine Innovation Centers (Contract 75N93019C00051, to the Krammer laboratory), the National Cancer Institute Cancer Center (Grant P30 CA91842, to the Siteman Cancer Center [The Genome Technology Access Center in the Department Publisher Copyright: {\textcopyright} 2020 American Association of Immunologists. All rights reserved.",
year = "2020",
month = aug,
day = "15",
doi = "10.4049/jimmunol.2000583",
language = "English",
volume = "205",
pages = "915--922",
journal = "Journal of Immunology",
issn = "0022-1767",
number = "4",
}